Understanding the reality: Is India losing standing for clinical research?

S. Parekh, S. Shewale
{"title":"Understanding the reality: Is India losing standing for clinical research?","authors":"S. Parekh, S. Shewale","doi":"10.3109/10601333.2011.653570","DOIUrl":null,"url":null,"abstract":"In recent years, the growth of clinical research has gone up globally, and countries from Asia are gaining in importance. Being the preferred hub for clinical research because of its young, highly educated work-force, prevalence of all major diseases, and, most importantly, use of English as the medium of communication and documentation making, India is an attractive destination. While enduring growth; few countries have made substantial changes to align with the international standards, wherein the state of affair is still in the process of improvement in India. Also, because of the ever growing hurdles for conducting trials in India, many clinical research sponsors have started searching for other suitable alternatives. Seemingly minor details could have a great impact on the outcome of the trial, not just in terms of time and money, but also the quality and credibility of the data generated. While there are a lot of similarities with that of Western standards of clinical research, there are indeed some key differences as well. Thus, India needs to take the next step up the value ladder to magnetize the global clinical research to outsource, drug discovery and development projects to India, to accelerate timelines and manage complexity. This article attends to various pieces of the same puzzle.","PeriodicalId":10446,"journal":{"name":"Clinical Research and Regulatory Affairs","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research and Regulatory Affairs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/10601333.2011.653570","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

In recent years, the growth of clinical research has gone up globally, and countries from Asia are gaining in importance. Being the preferred hub for clinical research because of its young, highly educated work-force, prevalence of all major diseases, and, most importantly, use of English as the medium of communication and documentation making, India is an attractive destination. While enduring growth; few countries have made substantial changes to align with the international standards, wherein the state of affair is still in the process of improvement in India. Also, because of the ever growing hurdles for conducting trials in India, many clinical research sponsors have started searching for other suitable alternatives. Seemingly minor details could have a great impact on the outcome of the trial, not just in terms of time and money, but also the quality and credibility of the data generated. While there are a lot of similarities with that of Western standards of clinical research, there are indeed some key differences as well. Thus, India needs to take the next step up the value ladder to magnetize the global clinical research to outsource, drug discovery and development projects to India, to accelerate timelines and manage complexity. This article attends to various pieces of the same puzzle.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解现实:印度正在失去临床研究的地位吗?
近年来,全球临床研究增长迅速,亚洲国家的重要性日益提高。作为临床研究的首选中心,由于其年轻、受过高等教育的劳动力、所有主要疾病的流行,以及最重要的是,使用英语作为交流和文件制作的媒介,印度是一个有吸引力的目的地。同时持久增长;很少有国家做出实质性的改变以与国际标准保持一致,其中印度的事态仍在改善过程中。此外,由于在印度进行试验的障碍越来越大,许多临床研究赞助商已经开始寻找其他合适的替代方案。看似微不足道的细节可能会对试验结果产生巨大影响,不仅在时间和金钱方面,而且在所生成数据的质量和可信度方面。虽然与西方的临床研究标准有很多相似之处,但也确实存在一些关键的差异。因此,印度需要在价值阶梯上迈出下一步,吸引全球临床研究外包,药物发现和开发项目到印度,以加快时间表和管理复杂性。这篇文章关注同一个谜题的不同部分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Changes to protocol in the regulation of adverse drug reactions – historical and current European view Policy and regulations in light of the human body as a ‘superorganism’ containing multiple, intertwined symbiotic relationships Community pharmacists’ knowledge and perceptions on risk management plans in the Southern Region of Portugal Increasing the odds of effective drug development: Elevating regulatory affairs professionals to strategic partners Current regulatory challenges and approaches in the registration of herbal drugs in Europe
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1